Physician profile
Thu Mindy Ly
NPI 1639455140
$8,683.86
in general payments reported to CMS, 2019-2025
58 companies · $800 in 2025
The $800 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $864 · 2021: $1,660 · 2022: $872 · 2023: $1,889 · 2024: $1,159 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,848.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,016.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $665.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $626.33 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $616.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $514.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.65 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $398.69 | 2019-2023 | Belsomra, Steglatro, Segluromet |
| Exact Sciences Corporation | $320.50 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $293.36 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $271.49 | 2019-2022 | |
| Amarin Pharma, INC. | $256.81 | 2019-2022 | |
| Eisai INC. | $169.62 | 2020-2022 | |
| Allergan, INC. | $140.24 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.33 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.